According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
Bayer said Monday that the European Medicines Agency had approved Vitrakvi for NTRK fusion-positive cancers. The drug won U.S. Food and Drug Administration accelerated approval in November.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
According to an analysis, evidence pointed to a Chinese hacking group. German drugmaker Bayer was also targeted in April, apparently by Chinese hackers who used the same malware.
Among 29 patients, the drug - designed for patients who become resistant to TRK inhibitors like Vitrakvi - showed a 34 percent response rate, according to Phase I data.
A roundup of some of the biggest trends and events in pharmaceuticals, biotechnology and diagnostics in 2018, including regulatory approvals, international trends, national policy and more.
An oncologist compared NTRK fusion patients to a needle in a haystack, but had some clues of how to find them. Still, drugs like Vitrakvi call for genomic sequencing of all cancer patients, he said.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
During a panel at MedCity INVEST, four experts addressed what VCs and potential acquirers are looking for in emerging companies.
Ahead of his participation in a breakout panel at MedCity INVEST in May, Bayer's U.S. head of digital innovation Dirk Schapeler discussed his role unique role finding and partnering with compatible digital companies around the world.
The German life sciences company plans to bring its accelerator program for digital health startups to San Francisco. It's now available in Berlin, Moscow, and Shanghai among other places.
The companies will develop new therapeutics targeted at blood disorders, blindness and congenital heart disease.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
An interview with Martin Shkreli four years ago when he was heading up his first biotech company, Retrophin
In a long-awaited deal, Bayer has sold its diabetes unit to Panasonic for $1.13 billion, thanks to growing competition from next-gen diabetes monitors.
Cambridge firm Flagship Ventures just announced a series of corporate partnerships to flesh out early stage funding for its portfolio companies and scale its in-house accelerator, VentureLabs. It just teamed up with AstraZeneca, Nestlé Health Science and Bayer CropScience, using each of the companies’ market knowledge – and pipeline for product development and commercialization. The trio also have […]
TOP STORIES Unrest in Baltimore is affecting healthcare for many people in ways that are unfortunately under the radar compared to the constant news updates. DaVita HealthCare Partners Inc. has agreed to pay $495 million to settle a False Claims Act lawsuit that accused the Denver-based company of wasting significant amounts of iron and Vitamin […]
The folks at Stanford's Center for Law and the Biosciences put together a fantastic piece this weekend on what should come next - and why a ban makes currently sense - on human genetic engineering. But you should also try to choke down a large in-depth look at life-extension technology (hold the Vanilla Sky) and a fascinating gambit by Mindy Kailing's brother to get in to medical school - can you believe he dropped out?